WO2023020423 - ROR1 CAR OR ROR1 /CD19 DUAL CAR T CELLS FOR THE TREATMENT OF TUMORS
National phase entry:
Publication Number
WO/2023/020423
Publication Date
23.02.2023
International Application No.
PCT/CN2022/112449
International Filing Date
15.08.2022
Title **
[English]
ROR1 CAR OR ROR1 /CD19 DUAL CAR T CELLS FOR THE TREATMENT OF TUMORS
[French]
CELLULES CAR T DOUBLE ROR1/CD19 OU CAR ROR1 POUR TRAITER DES TUMEURS
Applicants **
SHANDONG BOAN BIOTECHNOLOGY CO., LTD.
IP Department Xuerui PENG
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
BOAN BOSTON LLC
PENG, Xuerui
IP Department
19 Presidential Way
Woburn, Massachusetts 01801, US
NANJING BOAN BIOTECHNOLOGY CO. LTD
PENG, Xuerui
IP Department
No. 28, Gaoxin Road, Jiangbei New District
Nanjing, Jiangsu 210031, CN
Inventors
ZONG, Mengqi
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
JIAO, Jie
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
FENG, Jianxia
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
HARRIS, Michael
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
KAI, Xin
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
ZHOU, Li
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
WANG, Ninghai
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
WEI, Liangjun
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
CHEN, Hao
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
WEN, Xian
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
DOU, Changlin
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
DONG, Chuangchuang
No. 39, Keji Avenue, High-Tech Zone
Yantai, Shandong 264670, CN
Priority Data
PCT/CN2021/113420
19.08.2021
CN
202210425699.0
29.04.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1396 | |
| EPO | Filing, Examination | 7012 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 606 | |
| USA | Filing, Examination | 6310 |
Total: 15912 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
An ROR1 CAR or ROR1/CD19 Dual CAR for the treatment of tumors. The T cells expressing ROR1 CAR or ROR1/CD19 Dual CAR can be stimulated by ROR1-positive or ROR1/CD19-positive cells, and have cytotoxicity against ROR1-positive or ROR1/CD19-positive cells.[French]
L'invention concerne un CAR double ROR1/CD19 ou un CAR ROR1 pour traiter des tumeurs. Les cellules T exprimant le CAR ROR1 ou le CAR double ROR1/CD19 peuvent être stimulées par des cellules ROR1-positives ou ROR1/CD19-positives, et ont une cytotoxicité contre les cellules ROR1-positives ou ROR1/CD19-positives.